Posted on June 18, 2013 by Sitemaster
A newly published study in the Annals of Internal Medicine has offered an analysis of the cost-effectiveness of “observation” as compared to immediate initial treatment for men diagnosed with low-risk, localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Uncategorized | Tagged: active surveillance, cost, life, low risk, observation, quality, quantity, Treatment, watchful waiting | 3 Comments »
Posted on June 17, 2013 by Sitemaster
According to a media release issued by the company earlier today, Johnson & Johnson has made a definitive agreement to acquire Aragon Pharmaceuticals, Inc., including all rights to Aragon’s androgen receptor antagonist program. … READ MORE …
Filed under: Uncategorized | Tagged: ARN-509 | 2 Comments »
Posted on June 15, 2013 by Sitemaster
New data from Zelefsky and his colleagues at Memorial Sloan-Kettering Cancer Center suggest that men who respond well to neoadjuvant androgen deprivation therapy (ADT) have better long-term outcomes after radiation therapy given with curative intent for localized prostate cancer. … READ MORE …
Filed under: Uncategorized | Tagged: adjuvant, ADT, androgen, deprivation, neoadjuvant, outcome, prognosis, radiation | 5 Comments »
Posted on June 13, 2013 by Sitemaster
Earlier today, the Supreme Court of the United States (SCOTUS) ruled against Myriad Genetics in an important gene patenting case that we have discussed frequently on this site in the past couple of years. … READ MORE …
Filed under: Uncategorized | Tagged: gene, Myriad, patent, SCOTUS | Leave a Comment »
Posted on June 13, 2013 by Sitemaster
According to reports in various media overnight and this morning, the government agency Public Health England has been authorized to start development of a true national database of cancer patients that is focused on accelerating the application of personalised medicine. See for example this report in The Daily Telegraph this morning. … READ MORE …
Filed under: Uncategorized | Leave a Comment »
Posted on June 12, 2013 by Sitemaster
According to the Report of the U.S. House of Representatives’ Committee on Appropriations (see p. 273) it is currently proposed that the Prostate Cancer Research Program of the Department of Defense’s Congressionally Directed Medical Research Program will again receive $80 million in funding for the financial year 2014. … READ MORE …
Filed under: Uncategorized | Tagged: CDMRP, DoD, funding, PCRP, research | 1 Comment »
Posted on June 6, 2013 by Sitemaster
We apologize for the delay in giving readers access to the latest Cure Panel Talk Show, in which Dr. Mark Rubin of Weill Cornell Medical Center in New York talks about current developments in the treatment of advanced forms of prostate cancer — and particularly neuroendocrine forms of the disease. … READ MORE …
Filed under: Uncategorized | Leave a Comment »
Posted on May 31, 2013 by Sitemaster
For those who would like a professional perspective on the “new” prostate cancer data to be presented at the annual meeting of the American Society of Clinical Oncology, starting today in Chicago … READ MORE …
Filed under: Uncategorized | Leave a Comment »
Posted on May 24, 2013 by Sitemaster
One of the more interesting sets of data on metastatic prostate cancer to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago this year will be some of the very earliest data from the STAMPEDE trial, which we have discussed in some detail in an earlier post. … READ MORE …
Filed under: Uncategorized | Tagged: control, metastatic, outcome, STAMPEDE, survival | Leave a Comment »
Posted on May 16, 2013 by Sitemaster
For readers who want to start hunting through the abstracts of the upcoming annual meeting of the American Society of Clinical Oncology (starting May 31 in Chicago), you can now click here to start looking through all the available information.
Filed under: Uncategorized | Leave a Comment »
Posted on May 16, 2013 by Sitemaster
The “New” Prostate Cancer InfoLink apologizes for a delay in letting readers know that on Wednesday the US Food & Drug Administration approved radium-223 dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, but no known visceral (i.e., soft tissue) metastases. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: castration-resistant, mCRPC, metastatic, radium-223, Xofigo | Leave a Comment »
Posted on May 14, 2013 by Sitemaster
The next prostate cancer Cure Panel Talk Show will be hosting Mark Rubin, MD of Weill Cornell Medical College on May 31 at 4:00 pm EST. The show will be co-hosted by Dan Zenka of the Prostate Cancer Foundation. … READ MORE …
Filed under: Uncategorized | Leave a Comment »
Posted on May 10, 2013 by Sitemaster
Last September we asked whether the Oncotype DX test for risk of prostate cancer developed by Genomic Health was “ready for prime time”. In a media release issued earlier this week, the company said that it was. However, there are a number of unresolved issues that are likely to impact the uptake of this new test. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Uncategorized | Tagged: DX, Oncotype, risk, significant | 4 Comments »
Posted on May 8, 2013 by Sitemaster
So the American Urology Association (AUA) is clearly “on a roll” when it comes to guidance on the detection and management of prostate cancer. This is the third new guidance document issued in a matter of days. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: adjuvant, guideline, radiation therapy, radical prostatectomy, salvage | 4 Comments »
Posted on May 2, 2013 by Sitemaster
Here is information from an eighth batch of abstracts of presentations to be given at the annual meeting of the American Urological Association (AUA). You can search these yourself if you go to this link. The meeting will be taking place in San Diego this year. … READ MORE …
Filed under: Uncategorized | Leave a Comment »